CHICAGO -- An article in a recent issue of the Journal of the American Medical Association gave Eli Lilly's osteoporosis drug Evista (raloxifene) a big boost as a potential heart attack preventative. Researchers in a four-year "Multiple Outcomes of Raloxifene Evaluation" study, funded by Eli Lilly, studied the effect of raloxifene in multicenter trials involving almost 8,000 osteoporotic post-menopausal women between November 1994 and September 1999. They found that women entering the study with an already increased risk of cardiovascular problems ended up lowering their risk of cardiac events when taking raloxifene by study's end.
More investigation, however, is needed. "Before raloxifene is used for prevention of cardiovascular events," the researchers said, "these findings require confirmation in trials with evaluation of cardiovascular outcomes as the primary objective."
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group